Sembrix tablets 20mg

Sembrix tablets 20mg, manufactured by Novartis Pharma, contains Asciminib Hydrochloride (YJ code: 4291077F1027, standard: 20mg 1 tablet). This medication is a Bcr-Abl tyrosine kinase inhibitor that uniquely targets the ABL myristoyl pocket (STAMP). It is used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, including cases with the T315I mutation or resistance to other TKIs.